Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. develops investigational therapies for genetically driven neuromuscular diseases using its FORCE platform, which is designed to deliver payloads to muscle tissue and the central nervous system. Company news centers on clinical programs in Duchenne muscular dystrophy and myotonic dystrophy type 1, including z-rostudirsen, z-basivarsen, the DELIVER, ACHIEVE and HARMONIA studies, and preclinical work in additional neuromuscular diseases.
Recurring updates include clinical data presentations, FDA interactions and designations, financial results, cash-resource commentary, medical-conference abstracts, access-related research, investor conference participation and Nasdaq inducement equity grants.
Dyne Therapeutics (Nasdaq: DYN) has priced its initial public offering (IPO) of 12,251,578 shares at $19.00 each, aiming for gross proceeds of approximately $233 million before expenses. The IPO is set to begin trading on the Nasdaq Global Select Market on September 17, 2020, with the offering expected to close on September 21, 2020. The underwriters have an option to purchase an additional 1,837,736 shares within 30 days. J.P. Morgan, Jefferies, Piper Sandler, and Stifel are serving as joint book-running managers for the offering.